Obiective: To determine the efficacy and safety of intravitreal injection of ganciclovir for active cytomegalovirus (CMV) retinitis in AIDS patients who are intolerant of systemic ganciclovir therapy.
Methods: An open-labeled trial of intravitreal ganciclovir induction and maintenance therapy was conducted in outpatient clinics of five AIDS Clinical Trials Units. Sixteen eyes of 11 patients were treated; 11 eyes of eight patients were included in the analysis. Patients were treated with a series of two intravitreal injections per week for the first 3 weeks (induction period), followed by one injection per week until an endpoint was reached or for a total of 24 weeks. Each injection contained 200 ug ganciclovir in a total volume of 0.1 mL, administered through a 30-gauge needle. The primary endpoint measures were the time to retinitis progression as evidenced by the development of a new lesion or progression by more than 750 pm of a preexisting lesion, and progression of CMV as evidenced by development of active disease in the untreated eye or at an extraocular site. Other outcome measures were changes in visual acuity and adverse events related to the intravitreal injections.
Results: All of the treated eyes responded to induction therapy, and three eyes were successfully reinduced a total of four times. Median time to retinitis progression was 8.9 weeks (range, 6-20 wk). Cytomegalovirus disease of the untreated fellow eye or at an extraocular site occurred in four of seven patients (57%) for whom adequate follow-up data exist, at a mean of 11.7 weeks of study. lntravitreal injections were well-tolerated, and all complications were transient and reversible.
Conclusions: lntravitreal ganciclovir therapy is effective for the treatment of active CMV retinitis, with median times to retinitis progression comparable to those achieved with systemic therapy, and may be administered with minimal complications. However, the frequent occurrence of CMV disease in the untreated fellow eye and at extraocular sites suggests that when used as sole therapy, intravitreal treatment should be given for short periods of time, when systemic therapy is not possible. Cytomegalovirus (CMV) retinitis is the most frequent ophthalmic opportunistic infection seen in patients with acquired immunodeficiency syndrome (AIDS). The risk of developing CMV retinitis increases the longer the CD4 lymphocyte count is below 50/mm3, with a median time to diagnosis of 13 months.'x2 After 2 years of observation, over 40% of such patients will have developed retinitis. ' Intravenously administered ganciclovir and foscarnet are effective therapies and are approved for CMV retinitis in AIDS patients -3 15; however, chronic administration is required in order to prevent reactivation of disease, and breakthroughs are common. Intravenous ganciclovir therapy is commonly complicated by neutropenia, which may be dose-limiting, requiring suspension or discontinuation of therapy.3-9 Foscarnet is nephrotoxic and has been associated with mineral and electrolyte imbalances.1°-15 Although withholding ganciclovir typically allows for recovery of the granulocyte count, such discontinuous therapy may allow intervening reactivation of the retinitis and further retinal destruction. Prior to the availability of hematopoietic growth factors such as granulocyte-or granulocyte/macrophage-colony stimulating factors (G-CSF, GM-CSF), discontinuous ganciclovir therapy occurred regularly and probably contributed to early retinitis progression.
Since the original report of Hem-y and colleagues in 1987,16 establishing the technique of intermittent intravitreal ganciclovir injection, several small case series of the use of such therapy have been reported."-19 In general, these studies have demonstrated effective suppression of retinitis for several weeks, usually until the neutropenia resolves. Heinemann has reported that such therapy is safe and effective over as long as 56 weeks. 20 This report presents results of a multicenter trial of open-labeled intravitreal ganciclovir salvage therapy in patients with active CMV retinitis who are intolerant of systemic ganciclovir therapy. As neither foscarnet nor G-CSF were approved when this study was designed, this study represented one of the investigational salvage options available to patients at the time.
SUBJECTS AND METHODS
Patients were eligible if they met the 1987 CDC surveillance definition for AIDS and had active CMV retinitis, in one or both eyes, despite previous systemic ganciclovir therapy They either had to have experienced doselimiting toxicity or must have been unable to initiate systemic ganciclovir due to neutropenia (absolute neutrophil count of less than 750/mm3). The diagnosis of CMV retinitis was made by indirect ophthalmoscopy and documented by fundus photography. Exclusion criteria included concurrent treatment with systemic ganciclovir or foscarnet, CMV hyperimmune globulin, G-or GM-CSF; thrombocytopenia (platelet count <25,000/mm3); obvious external ocular infection; and ocular media opacities that might preclude adequate visualization of the retina and optic nerve.
As the study was originally conceived, patients' eyes with non-sight-threatening retinitis (lesions >3000 pm from the fovea and/or 1500 microns from the optic disk) were to be randomized independently to either immediate or deferred therapy, with therapy instituted when progression was demonstrated. Eyes with sight-threatening retinitis (lesions within 3000 pm of the fovea and/or 1500 microns from the optic disk) were treated immediately. Patients with bilateral sight-threatening retinitis and salvageable vision for whom appropriate systemic therapy was not available were allowed to receive concurrent bilateral intravitreal therapy at the discretion of their physician. Bilateral therapy was also allowed if CMV retinitis occurred or progression was demonstrated in the contralateral eye of patients presenting with uniocular disease. Because of poor accrual into the randomized portion of the study (one patient), the protocol was amended to eliminate randomization.
Ganciclovir, pre-filled vials of sterile water, and normal saline for reconstitution were supplied by Syntex Research (Palo Alto, CA). This protocol was approved by the Institutional Review Boards at each of the participating sites.
All patients enrolled in the trial underwent baseline ophthalmologic examination, which included determination of best corrected visual acuity, using Snellen eye charts, slit-lamp biomicroscopy, indirect ophthalmoscopy, tonometry, and nine-field wide-angle fundus photography, Baseline fundus drawings were recorded by the examining ophthalmologist.
Additional studies included complete blood count with platelet count, prothrombin and partial thromboplastin times, and blood chemistry studies.
Follow-up ophthalmologic evaluations were performed twice weekly for the first 3 weeks and then weekly Fundus photography was repeated at weeks 1,3, and 4 and then at 4week intervals, and interpreted by the treating ophthalmologist in an unmasked fashion. Hematologic studies were performed every 2 weeks, and careful symptom-directed examinations for other manifestations of CMV disease were performed as indicated.
Induction therapy for all patients included an initial series of six injections, 200 ug/O.l mL per treatment, administered twice weekly for the first 3 weeks. Subsequent injections were administered once weekly, for a total of 24 weeks of therapy. Bilateral injections were performed at the same visit. Treatment could be continued for an additional 24 weeks on a case-by-case basis. The technique of injection was modeled after that previously reported.16~'sJ0 Ganciclovir was supplied as a sterile lyophilized powder, 500 mg per vial. This was reconstituted with 5 mL sterile water for injection (without preservatives) to yield a 100 mg/mL solution. When thoroughly dissolved, 0.2 mL (20 mg) of the solution was removed and added to a vial of 9.8 mL sterile normal saline (without preservatives), yielding a normal saline solution containing 2 mg ganciclovir/mL. Final volume for intravitreal injection was 0.1 mL (200 ug ganciclovir). The drug was administered within 2 hours of preparation. Injections were performed on an outpatient basis under topical anesthesia. Prior to injection, the conjunctivae and fornices were irrigated with sterile saline and, in some cases, povidone-iodine solution. Injections were made 3.5 to 4.0 mm from the corneoscleral limbus in the inferotemporal quadrant. A 30-gauge, one-half inch needle was used for injection. Following injection, the patency of the central retinal artery was established ophthalmoscopically. Topical antibacterial drops were allowed the day before, the day of, and the day following treatment.
Primary ophthalmologic endpoints included the progression of retinitis, using the following criteria: development of a new retinal CMV lesion, advancement by 750 km or more of the border of any preexisting CMV lesion, or advancement to a new sector (one or more clock hour
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Journal 1996 positions) of lesions posterior to the equator. Secondary endpoints included changes in visual acuity of two lines (Snellen test) or more, or qualitative changes in disease activity as manifested by changes in the degree of opacification of the lesion border, and the development of extraocular CMV disease. Patients were eligible to remain on intravitreal therapy after an endpoint was reached if, in the opinion of the treating physicians, this was the best available therapy The statistical analysis includes simple descriptive statistics and product-limit methods for time-to-event estimates (medians).
RESULTS
Sixteen eyes of 11 patients were enrolled in this study from January 1990 to July 1991 at five AIDS Clinical Trials Units. Of these, three eyes (2 patients) were excluded from analysis because of ineligibility and two eyes (1 patient) were excluded because the patient died of HIVassociated encephalopathy during induction. This analysis, therefore, concerns 11 eyes from eight patients. Patient demographic data are presented in Table 1 . The patients ranged in age from 34 to 53 years (mean, 43 yr). All were homosexual men; six were white, and two, Hispanic. All patients had received previous therapy with intravenous ganciclovir and entered the study because of recrudescent CMIV retinitis and neutropenia requiring discontinuation of systemic ganciclovir therapy. All had ocular symptoms that included floaters and loss of vision. Information concerning the course of therapy for each eye is presented in Table 2 . Three patients had bilateral retinitis, and five had uniocular disease at entry. Ten of 11 eyes had sight-threatening retinitis at entry and received immediate treatment. Only one patient with bilateral disease was entered into the randomized portion of the study, with one eye treated immediately and the other, with non-sight-threatening disease, deferred until progression was documented. The eye randomized to deferred therapy required intravitreal ganciclovir after 3 weeks of observation because of progression. All treated eyes were followed clinically for a minimum of 4 weeks to a maximum of 3 1 weeks (mean, 12.7 wk on therapy, 17.8 wk on study), with receipt of 7 to 33 intravitreal injections over this period. Two patients came off study after completing the protocol, one dropped out early in order to receive chronic twice weekly intravitreal injections, and five patients died while on study Of these, four had developed progression of CMV disease prior to death. Though it was likely that CMV disease played a role in these deaths, none could be directly attributable to CMV disease. AU of the treated eyes responded to induction therapy. Within 2 to 3 weeks of beginning therapy, retinitis stabilized, with decreases in the degree of retinal necrosis and edema. However, this ophthalmologic response was not associated with a change in visual acuity from baseline. Retinitis progression was subsequently documented in 8 of 11 treated eyes. For the other three eyes, retinitis progression could not be documented, because one patient (two eyes) developed extraocular disease (CMV pneumonitis) at the end of the induction period, requiring systemic ganciclovir, and another patient (one eye) died of Staphylococcus aureus sepsis after 4 weeks on study For the eight remaining eyes, the product-limit estimate for median time to retinitis progression was 8.9 weeks (range for progressed eyes, 6 to 20 wk) (Figure 1) . Three of these eyes were successfully reinduced with intravitreal ganciclovir a total of four times.
Progression of CMY disease, regardless of site, was documented in all seven patients who survived beyond the third week of the study, at a median time of 8.5 weeks (range, 4 to 20 wk) (Figure 2 ). Cytomegalovirus disease of the fellow eye or at an extraocular site occurred in four of these seven patients (57%) at a mean time of 13.5 weeks (Table 3) . Gastrointestinal CMV disease developed in three cases (at weeks 10, 18, and 20), and pneumonitis, in one (week 4). Two of the patients who developed gastrointestinal disease simultaneously developed retinitis in the untreated fellow eye. All of these patients were treated with intravenous ganciclovir.
Treatment was generally well tolerated and no patients discontinued participation because of an adverse event. All severe (grades 3 and 4) complications of intravitreal injection were transient and reversible (Table 4) . There were no episodes of retinal detachment or endoph- thalmitis, the two most serious potential complications of intravitreal injection.
DISCUSSION
The diagnosis of CMV retinitis adds measurably to the morbidity associated with advanced HIV disease, not only due to the potential loss of vision but also because of the difficulty in treating this disease. The currently approved therapies, ganciclovir and foscarnet, although effective, are relatively difficult to administer and are often associated with dose-limiting toxicity. Both must be administered on a daily basis, usually via an indwelling central catheter. Catheter management may be difficult, especially for patients with decreased visual acuity and distorted depth perception. Nearly all such catheters will become infected, resulting in catheter-related bacteremia.15 Dose-limiting neutropenia occurs in up to 20% of AIDS patients treated for CMV retinitis with intravenous ganciclovir, and although currently many may be managed with the hematopoietic growth factors G-or GM-CSF, these agents were not available by prescription when this trial was in progress. Foscarnet therapy is frequently associated with nephrotoxicity and/or mineral and electrolyte disturbances. It is therefore desirable to have a local therapy available for those periods during which systemic therapy is not possible. Intravitreal therapy provides such an option. In this study the median time to retinitis progression of 8.9 weeks was similar to that in the largest study of systemic therapy of CMV retinitis,15 suggesting that this form of local therapy is effective. Although retinitis is the most common manifestation of CMV disease in patients with AIDS,' CMV infection is generally thought of as a systemic disease with viremia that may lead to other endorgan involvement.
It is surprising, therefore, that extraocular CMV is only rarely reported in the previously published case series of intravitreal ganciclovir therapy. l'-'O The authors found development of CMV disease beyond the treated eye, occurring either as disease in the untreated fellow eye or at some extraocular site, to be an important shortcoming of intravitreal therapy: 57% of patients had CMV disease documented elsewhere during the study Intravitreal therapy was particularly well tolerated in this study, with only transient and reversible adverse effects and a notable lack of retinal detachment or endophthalmitis.
Recently, an implantable intraocular device that releases ganciclovir in a sustained fashion over 4 to 8 This sustained-release implant has the advantage of a single surgical procedure (that may have to be repeated after the ganciclovir is spent) rather than weekly intravitreal injections, which are associated with adverse events ranging from mild discomfort to repeated deformation of the globe and violation of the vitreous and, in extreme cases, sight-threatening endophthalmitis and retinal detachment.
As was the case in the present study, disease in the fellow eye (67%) and at extraocular sites (3 1%) was observed frequently when the implant was used as sole therapy for retinitis.*l Others have attempted intravitreal injections of up to 2 mg ganciclovir per 0.1 mL with good results. 22 This study demonstrates that although local therapy delivered by intravitreal injection is effective at controlling retinitis, disease in the untreated fellow eye and at extraocular sites occurs regularly and is a serious limitation. Results suggest that intravitreal therapy, as the sole treatment for CMV retinitis, is most suitable only for short periods, when systemic therapy is not possible.
Although the treatment options available to patients with CMV retinitis remain limited, one can imagine treatment strategies that utilize systemic therapy to bring disease under initial control, followed by combinations of systemic and local therapy to delay retinitis progression, and to protect the uninvolved eye and extraocular sites. Clinical trials aimed at developing such multimodality treatment strategies are underway and promise to advance the standard of care for CMV retinitis in patients with AIDS.
